Physician profile
Bindi N Patel
NPI 1235125543
$1,323.30
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $111 · 2021: $253 · 2022: $51.99 · 2023: $363 · 2024: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $591.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.41 | 2019-2021 | |
| Abbott Laboratories | $210.67 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Pulmonx Corporation | $140.21 | 2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| E.R. Squibb & Sons, L.L.C. | $113.40 | 2023 | |
| Boston Scientific Corporation | $110.56 | 2019 | |
| Oyster Point Pharma, INC. | $104.96 | 2023 | Tyrvaya |
| Medtronic, INC. | $101.29 | 2021 | |
| Nestle Healthcare Nutrition INC. | $99.90 | 2020 | |
| Zimvie INC. | $88.63 | 2024 | |
| Johnson & Johnson Health Care Systems INC. | $50.88 | 2021 | |
| Cardiva Medical, INC. | $16.83 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bindi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.